Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibioprophylaxis for Excision-graft Surgery in Burn Patients (A2B)
NCT04292054Phase 3Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Oct 2020
- Primary completion
- Apr 2026
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cefazolin and piperacillin + tazobactam in burn injury (2 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Post-operative infection at 7 days, Post-operative sepsis at 7 days and 2 more. Started Oct 2020; status: recruiting.
02
Drugs
cefazolinpiperacillin + tazobactam
03
Conditions
burn injury
Beyond the preview
Go deeper on NCT04292054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04292054.